SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata (INOD) is trending amid intense community debate surrounding an eagerly anticipated strategic partnership announcement, which the CEO indicated would occur soon, potentially with a defense sector leader. While many bulls foresee this deal solidifying INOD's market leadership in AI data training and government contracts, a vocal skeptical faction expresses frustration over past unfulfilled predictions and general market conditions affecting small-cap AI stocks.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is currently trending due to a surge in cannabis-themed meme coins like $WEEDCOIN, which are seeing significant community-driven gains following reclassification news impacting the sector. While much of the conversation focuses on the bullish momentum and retail frenzy around these specific tokens, the broader community is also discussing Solana's market performance and recent legal developments.

Midnight is a privacy-first blockchain that blends public verifiability with confidential data handling. You can use Midnight's selective disclosure and ZK proofs to build apps.

Midnight

Midnight ($NIGHT) is commanding significant market attention, driven by its current price action and exceptionally high trading volumes. The crypto community is actively debating its privacy-centric utility, strategic position within the Cardano ecosystem, and the effects of recent token distributions. Sentiment ranges from strong bullish predictions to cautious discussions about its long-term sustainability.

UNI is the governance token for Uniswap, an Automated Market Marker DEX on the Ethereum blockchain. The UNI token allows token holders to participate in the governance of the protocol. Key decisions such as usage of the treasury or future upgrades can be decided through a governance vote.

UniSwap

Uniswap is trending amidst strong anticipation for a crucial governance proposal to activate its protocol fee switch and implement a substantial token burn mechanism. The community is actively discussing the potential for the UNI token to become deflationary, which is widely expected to enhance its value and attract significant interest. These proposed changes are seen as a pivotal step toward unlocking new revenue streams for holders and reinforcing Uniswap's strength within the decentralized finance ecosystem.

Exchange Traded Concepts Trust - ROBO Global Robotics and Automation Index ETF

Exchange Traded Concepts Trust - ETCT ROBO Global Robotics and Automation Index ETF

The ROBO Global Robotics and Automation Index ETF is trending as the community eagerly discusses the accelerating physical AI and robotics revolution, bolstered by recent advancements in humanoid robotics and significant investments from industry leaders. Many investors see ROBO as a top diversified vehicle to capitalize on this transformative sector, expecting robots to increasingly address labor needs and redefine industries.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

WEEDCOIN is experiencing a surge in attention, driven by the significant federal reclassification of cannabis, which the community views as a major catalyst for the entire sector. The Solana-based token's strong performance has fueled a retail frenzy, with supporters emphasizing its robust global cannabis culture community and positioning it as a key beneficiary of the shifting regulatory landscape.

Aave is a decentralized money market protocol where users can lend and borrow cryptocurrency across 20 different assets as collateral. The protocol has a native token called AAVE, which is also a governance token that lets the community decide the direction of the protocol in a collective manner. Lenders can earn interest by providing liquidity to the market, while borrowers can borrow by collateralizing their cryptoassets to take out loans from the liquidity pools.

AAVE

Aave is trending as the community highlights its superior product-market fit and aggressive expansion, including the Aave V4 testnet, a new consumer savings app challenging traditional finance, and a proposed $50 million annual token buyback. Community discussion frequently contrasts Aave's strong market share and innovative features with competitors, positioning it as a leading DeFi protocol poised for significant growth and mainstream adoption.

Flora Growth Corp. engages in the production of organic cannabis and pharmaceutical-grade medical products. It operates through the following segments: House of Brands and Commercial and Wholesale. The House of Brands segment includes multiple categories including food and beverage, nutraceuticals, cannabis accessories and technology, personal care and wellness. The Commercial and Wholesale segment includes distribution of pharmaceutical products to international markets. The company was founded on March 13, 2019 and is headquartered in Fort Lauderdale, FL.

Flora Growth Corp

Flora Growth (FLGC) is trending due to its recent pivot and rebranding to ZeroStack, focusing on decentralized AI with a significant crypto treasury of 0G tokens. The community is actively discussing the substantial valuation gap between its reported crypto assets and its micro market capitalization, fueling speculation of a massive short squeeze due to its extremely low float. This strategic shift, alongside shareholder approval for a future forward stock split, has ignited fervent bullish sentiment, drawing comparisons to past high-flying low-float plays.

- Maple is 'DeFi's Institutional Lender'. Maple Finance lending engine powers institutional yield for both Maple and Syrup; providing lenders with institutional quality yield overcollateralized by digital assets. The protocol combines the best of institutional lending and DeFi. Syrup is the team's newest product, offering permissionless access to Maple's lending engine whilst also integrated with the broader DeFi ecosystem including Balancer and Pendle Finance.

Syrup

SYRUP is experiencing heightened attention following a recent high-profile exchange listing and its strong positioning as a Real World Asset (RWA) and tokenization leader. The community widely views the asset as significantly undervalued compared to similar projects, anticipating a substantial repricing as institutional engagement in DeFi continues to expand. Discussion also centers on Maple Finance's strategic shift to a revenue-driven token buyback model, which is seen as a key catalyst.

PulteGroup, Inc. engages in the homebuilding business. The firm is also involved in mortgage banking and title and insurance brokerage operations. It operates through the Homebuilding and Financial services business segments. The Homebuilding segment includes operations from Connecticut, Maryland, Massachusetts, New Jersey, New York, Pennsylvania, Virginia, Georgia, North Carolina, South Carolina, Tennessee, Florida, Illinois, Indiana, Kentucky, Michigan, Minnesota, Missouri, Ohio, Texas, Arizona, California, Nevada, New Mexico, and Washington. The Financial Services segment is composed of mortgage banking and title operations. The company was founded by William J. Pulte in 1950 and is headquartered in Atlanta, GA.

PulteGroup Inc

PulteGroup is trending following strong quarterly financial results and significant share repurchase authorizations, signaling management confidence in its operational model. The community remains divided, with some anticipating sustained demand from structural housing shortages and potential mortgage rate relief, while others express caution regarding persistent affordability challenges and sector-wide margin pressures due to incentives.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Assenagon Asset Management S.A. Lowers Holdings in BioCryst Pharmaceuticals, Inc. $BCRX

Assenagon Asset Management S.A. reduced its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 14.6% during the 3rd quarter, according to its most recent filing with the...

Q4 Earnings Estimate for BCRX Issued By HC Wainwright

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Analysts at HC Wainwright issued their Q4 2025 earnings per share estimates for shares of BioCryst Pharmaceuticals in a report issued on...

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Rating of "Moderate Buy" from Analysts

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the fourteen ratings firms that are currently covering the...

<ul class="summary-bullets"><li>BioCryst said the approval follows positive interim data from a trial that showed the drug is safe and well-tolerated.</li><li>The company is also seeking approval for the drug’s use in the targeted age group in Europe, Japan, Canada, and other countries.&nbsp;</li><li>Orladeyo in capsule form is already FDA-approved for treating the disorder in those over 12 years of age.&nbsp;</li></ul>BioCryst Pharmaceuticals, Inc. (BCRX) has received approval from the U.S. Food and Drug Administration (FDA) for Orladeyo, an oral pellet formulation for the treatment of a rare genetic disorder in children.The approval comes after positive interim data from the APeX-P trial, which showed it is safe and well-tolerated and effectively reduces monthly HAE attacks in young children, the company said in a statement.BioCryst has also filed an application for the drug’s use with the European Medicines Agency and the Japan Pharmaceutical and Medical Devices Agency. The company said it is exploring additional regulatory filings in other global territories, including Canada.Shares of <a href="https://stocktwits.com/symbol/BCRX">BCRX</a> jumped over 4% on Friday morning at the time of writing.<h2 class="st-heading-2">Breakthrough Treatment For Young Children</h2>Hereditary angioedema (HAE) is a rare genetic disorder that can cause sudden and severe swelling in the skin, face, limbs, gut, and air pathways with potential life-threatening consequences.Orladeyo will become the first approved oral drug for the treatment of hereditary angioedema (HAE) in children aged 2 to 12, the company said. All other treatments for HAE in the market for the targeted demographic are currently administered intravenously or through injections.A capsule formulation of Orladeyo for treating HAE in children over 12 years and older adults received FDA approval in December 2020.“As we mark five years since ORLADEYO first transformed care for those with HAE ages 12 and older, this approval extends the benefits of oral prophylactic therapy to a vulnerable and important part of the HAE community, children ages 2 to less than 12. We couldn’t be more excited to bring this treatment option to these kids and their caregivers,” said Jon Stonehouse, chief executive officer of BioCryst.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, BCRX was among the top five trending stocks on Friday morning. The retail sentiment around BCRX jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume remained ‘high’ at the time of writing.<figure class="image"><img style="aspect-ratio:1267/136;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_12_at_6_36_49_PM_png_130ee4212d.webp" alt="BCRX sentiment and message volume on Stocktwits. " width="1267" height="136"></figure>One Stocktwits user commended the FDA news.<stembedurl>https://stocktwits.com/Kiwiarse/message/638975638</stembedurl>Shares of BCRX are down over 3% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

CANADA - 2025/10/14: In this photo illustration, the BioCryst Pharmaceuticals (Bio Cryst) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Are Retail Traders Going Gaga Over BioCryst Pharma Stock Today?

The FDA has approved the use of Orladeyo, an oral drug, for children aged 2–12 with a rare genetic disorder.

Equity

Hood River Capital Management LLC Buys New Holdings in BioCryst Pharmaceuticals, Inc. $BCRX

Hood River Capital Management LLC purchased a new position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) in the 2nd quarter, according to its most recent 13F filing with the...

BioCryst Pharmaceuticals, Inc. $BCRX Shares Acquired by Russell Investments Group Ltd.

Russell Investments Group Ltd. increased its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 326.1% during the 2nd quarter, according to its most recent filing with...

JPMorgan Chase & Co. Grows Holdings in BioCryst Pharmaceuticals, Inc. $BCRX

JPMorgan Chase & Co. boosted its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 48.7% during the 2nd quarter, according to its most recent 13F filing with the...

BioCryst Pharmaceuticals, Inc. $BCRX Position Increased by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership grew its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 2,103.7% in the 2nd quarter, according to the company in its most recent...

BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Alane Barnes Sells 19,770 Shares

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) insider Alane Barnes sold 19,770 shares of the business's stock in a transaction on Wednesday, December 3rd. The stock was sold at an...

Insider Selling: BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Sells 50,906 Shares of Stock

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) insider Alane Barnes sold 50,906 shares of the company's stock in a transaction dated Tuesday, December 2nd. The stock was sold at an...

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	$0.04	--	--	N/A
Q3 '25	$0.04	$0.06	50.75%	BEAT
Q2 '25	$0.01	$0.02	185.71%	BEAT
Q1 '25	-$0.08	$0.00	100.00%	BEAT
Q4 '24	-$0.05	-$0.13	-182.61%	MISSED

BCRX
Biocryst Pharmaceuticals Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest BCRX News

BCRXBiocryst Pharmaceuticals Inc.